Video Shorts

0:55

Tackling the Barriers to Cervical Cancer Screening

9 months ago

Robert Neff, MD

4:00

OncLive Recognizes World Cancer Day

9 months ago

Ronac Mamtani, MD, MSCE(+3 more)

0:43

Unpacking OS Data from the ROSELLA Trial

9 months ago

Alexander B. Olawaiye, MD

Justin Call, MD, and D. Ross Camidge, MD, PhD

2:11

How I Discovered My True Calling in Oncology

9 months ago

Ross Camidge, MD, PhD(+1 more)

1:43

Optimizing HPV Vaccination for Cancer Prevention

9 months ago

Maurie Markman, MD

1:49

Implications of FDA Draft Guidance on MRD End Points in Myeloma Trials

9 months ago

Rahul Banerjee, MD

0:21

Outlining the Results of the HER2CLIMB-05 Trial in HER2+ Breast Cancer

9 months ago

Erika P. Hamilton, MD

0:54

Increasing Clinical Trial Access in Gynecologic Oncology

9 months ago

Katherine Kurnit, MD, MPH

1:25

Highlighting the Importance of the Bionic Breast Program

9 months ago

Stacy Tessler Lindau, MD, MA

0:38

The Role of Clinical Trials in Gynecologic Oncology

9 months ago

John Moroney, MD

1:22

Expert Insight on AI in Oncology and Clinical Trials at University of Chicago Comprehensive Cancer Center

9 months ago

Riley Kandel

1:18

Examining the Future of Bispecifics and CAR T-Cell Therapy in Lymphoma

9 months ago

Alexandra Rojek, MD

Molecularly Driven Therapies Drive Ongoing Research in MPNs

1:48

Molecularly Driven Therapies Highlight Ongoing Research in MPNs

9 months ago

John O. Mascarenhas, MD

1:06

Addressing the Need for Cancer Screening in Young Adults

9 months ago

Sonali M. Smith, MD

1:16

Unpacking the Future of AI in Oncology

9 months ago

Alexander T. Pearson, MD, PhD

1:22

MRD as a Surrogate End Point in Multiple Myeloma Trials

9 months ago

Marc J. Braunstein, MD, PhD

0:1.44

How HPV Testing Can Fall Through the Cracks in Cervical Cancer

9 months ago

Dana Chase, MD

2:06

FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

9 months ago

David A. Braun, MD, PhD

1:04

How Butyrate Loss Affects Post-Transplant Outcomes in Myeloma

9 months ago

Pooja Phull, MD

1:03

Could Zanidatamab Replace Trastuzumab As the Gold Standard in First-Line HER2+ Gastric Cancer?

9 months ago

Manish A. Shah, MD

0:34

Role of Bridging Therapy Before CAR T-Cell Therapy in Myeloma

9 months ago

Matthew J. Frigault, MD

1:34

The Importance of HPV Vaccination in Oncology

9 months ago

Maurie Markman, MD

1:09

The Significance of the FDA Approval of Subcutaneous Daratumumab for Smoldering Multiple Myeloma

9 months ago

Peter Voorhees, MD

Laura Alder, MD, Eric K. Singhi, MD, and Paolo Tarantino, MD, PhD.

2:01

Quick Takes: Bridging the Gaps in Brain Mets, Continued

9 months ago

Paolo Tarantino, MD(+2 more)

0:51

Unpacking Real-World Data in mCRC

9 months ago

Rocio Garcia-Carbonero, MD, PhD

Jason Mouabbi, MD, Manmeet Ahluwalia, MD, MBA, FASCO, Laura Alder, MD.

1:45

Quick Takes: Bridging the Gaps in Brain Mets

9 months ago

Jason Mouabbi, MD(+2 more)

1:58

Lingering Questions on the Earlier Use of Oral SERDs in ER+ Breast Cancer

9 months ago

Seth Wander, MD, PhD

1:02

Dr Singhi on the Emerging Role of TROP2-Directed ADCs in the Evolving Treatment Algorithm of NSCLC

9 months ago

Eric K. Singhi, MD

1:04

Clinical Decision-Making Around Local vs Systemic Therapy for Metastatic Lung Cancer With CNS-Only Disease

9 months ago

Laura Alder, MD

1:10

Patient-Level Clinical Trial Communication Skills For Hematology/Oncology Fellows

10 months ago

Carma L. Bylund, PhD

Trending on OncLive

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ESMO 2026

TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions

Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma

Video Shorts

Trending on OncLive

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ESMO 2026

TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions

Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma

Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R Myeloma

Roswell Park Researchers Identify Strategy for Overcoming Resistance to RAS-Targeted Cancer Drugs